mutares sells Suir Pharma Ireland

The Munich-based restructuring specialist mutares AG (ISIN: DE000A0SMSH2) has sold the pharmaceutical contract manufacturer Suir Pharma Ireland to the strategic investor Saneca Pharmaceuticals. With its second successful exit in 2015, mutares further streamlines its portfolio.

Suir Pharma Ireland (SPI) was acquired in 2012 from German STADA Group. It operates as a Contract Manufacturing Organisation (CMO) producing finished dosage formulations across a broad range of therapeutic areas for various customers worldwide and operates the only Independent Beta-Lactam FDA approved facility in Europe.

After successfully accomplishing the main challenge of making SPI a stand-alone pharmaceutical contract manufacturer, mutares has decided to sell SPI to Saneca Pharmaceuticals for an undisclosed amount. Hence, mutares continues to streamline its portfolio and to free up capacities for new transactions as the deal pipeline is very promising.

Saneca Pharmaceuticals is confident that this strategic acquisition will add significantly to the services that the Saneca Group can offer to its customers. Lubo Soltys, President of Saneca, commented: “We are delighted to have acquired Suir Pharma. We see the combined entity providing significantly enhanced pharmaceutical development capacity and tech transfer capabilities across a range of pharmaceutical forms. This will certainly provide easier access to various markets for our worldwide customer base.“

Company profile of Saneca Pharmaceuticals

Saneca Pharmaceuticals is a supplier to the global pharmaceutical and healthcare industry. Saneca develops and produces high quality pharmaceutical dosage forms, including oral solid, liquids, soft gel capsules and creams. In addition, Saneca Pharmaceuticals has a portfolio of synthetic API’s, and opiate API’s produced from plant biomass.

Company profile of Mutares SE & Co. KGaA

Mutares SE & Co. KGaA, Munich (www.mutares.de), acquires medium-sized companies and parts of groups with headquarter in Europe that are being sold in the course of a repositioning process at their owners and show a clear potential for operational improvement. Mutares actively supports and develops its portfolio companies with its own investment and consulting teams as well as through acquisitions of strategic add-ons. The aim is to achieve a clear value increase with a focus on sustainable, long-term growth of the portfolio company. In 2018, Mutares’ portfolio companies generated consolidated revenues of EUR 865 million and employed more than 4,700 people worldwide. The shares of Mutares SE are listed on Frankfurt Stock Exchange under the ticker symbol “MUX” (ISIN: DE000A2NB650).